TeraPore Technologies, a South San Francisco, CA-based developer of advanced nanofiltration membrane systems for bioprocess and other applications, completed a $6M Series A financing round.
The round was led by Anzu Partners with participation from RA Capital Management and Artiman Ventures as well as Wilson Sonsini Goodrich & Rosati.
The company intends to use the funds to accelerate product development and commercialization efforts.
Led by Dr. Rachel Dorin, founder and CEO, TeraPore Technologies develops and manufactures filters through a proprietary and scalable block copolymer self-assembly technology. When fabricated into membranes, the polymers spontaneously form into highly uniform structures, creating precise holes (or pores) on the nanoscale.
One particularly critical application for the technology is in the production process of biological drugs (or biologics) where a key step is the separation of viral contaminants from the drug material.
TeraPore was founded in 2013 as a spinout of Cornell University, and has received support from the National Institutes of Health (NIH), the National Science Foundation (NSF), and the Defense Threat Reduction Agency (DTRA).